Regulatory agencies should engage in drug pricing

BMJ 2016; 354 doi:
Authors: Raffaella Ravinetto, Gianluca Gaidano
“Mazzucato argues that drug pricing policies “must be completely transparent, so that governments can negotiate for better value on behalf of their populations.” She also observes that the US government never exercised its right to cap prices of drugs developed through publicly funded research.”
Find article here.